18-Methylaminocoronaridine

Summary

(−)-18-Methylaminocoronaridine (18-MAC) is a second generation synthetic derivative of ibogaine developed by the research team led by the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont.[1][2]

18-Methylaminocoronaridine
Identifiers
PubChem CID
  • 44325016
ChemSpider
  • 24721797 checkY
Chemical and physical data
FormulaC22H29N3O2
Molar mass367.493 g·mol−1
3D model (JSmol)
  • Interactive image
  • c4cccc1c4[nH]c3c1CCN2CC(C5)CC3(C(=O)OC)C2C5CCNC
  • InChI=1S/C22H29N3O2/c1-23-9-7-15-11-14-12-22(21(26)27-2)19-17(8-10-25(13-14)20(15)22)16-5-3-4-6-18(16)24-19/h3-6,14-15,20,23-24H,7-13H2,1-2H3/t14-,15+,20+,22-/m1/s1 checkY
  • Key:YKMOJVPLIUXEIP-SVBQBFEESA-N checkY
  (verify)

See also edit

References edit

  1. ^ Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, et al. (June 2003). "Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents". Journal of Medicinal Chemistry. 46 (13): 2716–30. doi:10.1021/jm020562o. PMID 12801235.
  2. ^ Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, Fleck MW (May 2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". European Journal of Pharmacology. 492 (2–3): 159–67. doi:10.1016/j.ejphar.2004.03.062. PMID 15178360.